Syncom Formulations Sees Technical Momentum Shift Amid Mixed Market Signals

Price Momentum and Recent Market Performance

On 10 Feb 2026, Syncom Formulations closed at ₹14.38, up from the previous close of ₹13.55, marking a robust daily gain of 6.13%. The stock traded within a range of ₹13.82 to ₹14.50 during the session, still well below its 52-week high of ₹23.46 but comfortably above the 52-week low of ₹11.52. This price action reflects a short-term bullish momentum, supported by a weekly return of 10.62%, significantly outperforming the Sensex’s 2.94% gain over the same period.

Over the last month, the stock has gained 9.52%, again outpacing the Sensex’s modest 0.59% rise. Year-to-date, Syncom has managed a slight positive return of 0.77%, contrasting with the Sensex’s decline of 1.36%. However, the one-year return remains negative at -22.02%, underscoring the challenges the company has faced in the recent past. Longer-term returns paint a more favourable picture, with a three-year gain of 96.99% and an impressive five-year return of 338.41%, far exceeding the Sensex’s 63.78% and 249.97% respectively over the same periods.

Technical Indicator Analysis: Mixed Signals but Improving Trend

The technical landscape for Syncom Formulations is nuanced. The overall technical trend has shifted from bearish to mildly bearish, signalling a tentative improvement but still cautioning investors. The Moving Average Convergence Divergence (MACD) indicator remains bearish on a weekly basis and mildly bearish monthly, indicating that while downward momentum is easing, it has not fully reversed.

The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, suggesting the stock is neither overbought nor oversold, which could imply a consolidation phase or a potential base-building period.

Bollinger Bands on weekly and monthly timeframes are mildly bearish, reflecting moderate volatility and a slight downward pressure on price. Daily moving averages also remain mildly bearish, indicating that short-term momentum has yet to decisively turn positive.

The Know Sure Thing (KST) oscillator aligns with this cautious tone, bearish on the weekly chart and mildly bearish monthly, reinforcing the view that momentum remains subdued but is showing signs of stabilisation.

Interestingly, Dow Theory analysis presents a mildly bullish weekly signal, suggesting that the broader trend may be attempting to establish a base for recovery, although the monthly trend remains without a clear direction.

On-Balance Volume (OBV) indicators show no trend on weekly or monthly charts, indicating that volume flow has not yet confirmed a strong directional move, which is often a prerequisite for sustained price advances.

Mojo Score Upgrade and Market Capitalisation Context

Syncom Formulations’ Mojo Score currently stands at 51.0, reflecting a Hold rating, an upgrade from the previous Sell grade assigned on 9 Feb 2026. This upgrade signals a shift in analyst sentiment, recognising the stock’s improving technical parameters and recent price momentum. The company’s market capitalisation grade is rated 4, indicating a relatively modest market cap within its sector but sufficient liquidity and investor interest to support trading activity.

Such an upgrade often encourages cautious accumulation by investors who had previously avoided the stock due to its bearish technical posture. The Hold rating suggests that while the stock is not yet a strong buy, it is no longer a sell, and investors should monitor developments closely for further confirmation of trend reversal.

Comparative Performance Within Pharmaceuticals & Biotechnology Sector

Within the Pharmaceuticals & Biotechnology sector, Syncom Formulations’ recent price momentum and technical signals are noteworthy. The sector has experienced mixed performance amid global supply chain challenges and regulatory pressures. Syncom’s ability to outperform the Sensex in the short term, with weekly and monthly returns well above benchmark indices, highlights its relative strength.

However, the stock’s one-year negative return of -22.02% compared to the Sensex’s 7.97% gain indicates that longer-term headwinds remain. Investors should weigh these factors carefully, considering both the company’s improving technical outlook and the broader sector dynamics.

Outlook and Investor Considerations

Technical indicators suggest that Syncom Formulations is at a critical juncture. The shift from bearish to mildly bearish trends, combined with a daily price surge and an upgraded Mojo Grade, points to a potential base formation and early signs of recovery. However, the absence of strong bullish signals from momentum oscillators like RSI and KST, and the lack of volume confirmation from OBV, counsel prudence.

Investors should watch for confirmation of trend reversal through sustained price moves above key moving averages and a bullish crossover in MACD. Additionally, a break above the recent high of ₹14.50 with increased volume could signal a more definitive shift in momentum.

Given the stock’s historical volatility and mixed technical signals, a Hold rating remains appropriate for now, with potential upgrades contingent on further positive developments.

Summary

Syncom Formulations (India) Ltd’s recent technical parameter changes reflect a cautious but meaningful shift in momentum. While the stock remains mildly bearish on several key indicators, the daily price jump and Mojo Grade upgrade to Hold suggest that the worst of the downtrend may be behind it. Investors should remain vigilant for confirmation signals such as improved MACD readings, RSI momentum, and volume trends before committing to a more bullish stance.

Long-term investors may find value in the stock’s strong multi-year returns, but short-term traders should balance optimism with the current mixed technical signals. The company’s performance relative to the Sensex and its sector peers will be critical in shaping future price trajectories.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →